Hyundai Bioscience Co., Ltd. (KOSDAQ: 048410)
19,430
-180 (-0.92%)
Sep 11, 2024, 10:45 AM KST
Hyundai Bioscience Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Net Income | -6,573 | -14,499 | -15,807 | -20,051 | -8,260 | 1,121 | Upgrade
|
Depreciation & Amortization | 1,007 | 1,435 | 1,782 | 2,703 | 3,778 | 3,813 | Upgrade
|
Loss (Gain) From Sale of Assets | - | - | - | - | - | 3.5 | Upgrade
|
Asset Writedown & Restructuring Costs | 4,769 | 4,769 | - | 7,517 | 2,829 | - | Upgrade
|
Loss (Gain) From Sale of Investments | -123.67 | -123.67 | -910.99 | - | - | - | Upgrade
|
Loss (Gain) on Equity Investments | -32.38 | - | -8,834 | -93.91 | -1,542 | 166.12 | Upgrade
|
Stock-Based Compensation | 126.67 | 402.42 | 596.94 | 578.26 | 1,032 | 753.05 | Upgrade
|
Provision & Write-off of Bad Debts | 134.72 | -28.78 | 5,260 | -583.99 | -212.84 | 206.52 | Upgrade
|
Other Operating Activities | -5,461 | 911.44 | -79.49 | 3,925 | 2,170 | 1,874 | Upgrade
|
Change in Accounts Receivable | 1,718 | 864.23 | 1,184 | 3,526 | 4,585 | 2,123 | Upgrade
|
Change in Inventory | 1,562 | 358.12 | 403.6 | 864.9 | 1,865 | -2,209 | Upgrade
|
Change in Accounts Payable | -182.67 | -256.2 | 503.57 | 13.43 | 1,355 | 1,445 | Upgrade
|
Change in Other Net Operating Assets | -136.55 | 159.77 | -642.06 | 1,063 | -97.7 | -117.65 | Upgrade
|
Operating Cash Flow | -3,194 | -6,008 | -16,544 | -538.48 | 7,502 | 9,179 | Upgrade
|
Operating Cash Flow Growth | - | - | - | - | -18.27% | 83.38% | Upgrade
|
Capital Expenditures | -130.21 | -539.7 | -1,544 | -3,747 | -25,204 | -3,065 | Upgrade
|
Sale (Purchase) of Intangibles | - | -47.84 | - | -15.12 | - | -10,000 | Upgrade
|
Investment in Securities | 10,994 | 6,000 | 10,210 | -13,010 | 941.66 | -2,927 | Upgrade
|
Other Investing Activities | -524.18 | -557 | -0.4 | 1,773 | 2.43 | -113.45 | Upgrade
|
Investing Cash Flow | -9,628 | 5,177 | 8,518 | -12,359 | -26,831 | -14,697 | Upgrade
|
Short-Term Debt Issued | - | - | - | - | 2,000 | - | Upgrade
|
Long-Term Debt Issued | - | - | - | - | 33,000 | 7,000 | Upgrade
|
Total Debt Issued | 31,753 | - | - | - | 35,000 | 7,000 | Upgrade
|
Short-Term Debt Repaid | - | -500 | -500 | - | - | - | Upgrade
|
Long-Term Debt Repaid | - | -362.88 | -1,194 | -1,246 | -1,182 | -948.42 | Upgrade
|
Total Debt Repaid | -585.12 | -862.88 | -1,694 | -1,246 | -1,182 | -948.42 | Upgrade
|
Net Debt Issued (Repaid) | 31,168 | -862.88 | -1,694 | -1,246 | 33,818 | 6,052 | Upgrade
|
Issuance of Common Stock | 206.55 | 1,094 | 3,596 | 4,449 | - | 2,110 | Upgrade
|
Other Financing Activities | -292.4 | -289.18 | -229.04 | -209.66 | -867.11 | -281.4 | Upgrade
|
Financing Cash Flow | 31,082 | -57.97 | 1,673 | 2,994 | 32,951 | 7,880 | Upgrade
|
Foreign Exchange Rate Adjustments | 17.7 | -31.72 | -103.42 | -122.29 | 37.95 | 30.74 | Upgrade
|
Miscellaneous Cash Flow Adjustments | 0 | - | - | - | -0 | - | Upgrade
|
Net Cash Flow | 18,278 | -920.54 | -6,456 | -10,026 | 13,660 | 2,393 | Upgrade
|
Free Cash Flow | -3,324 | -6,548 | -18,087 | -4,285 | -17,702 | 6,113 | Upgrade
|
Free Cash Flow Margin | -35.97% | -69.06% | -230.36% | -46.37% | -141.49% | 20.32% | Upgrade
|
Free Cash Flow Per Share | -83.47 | -164.62 | -459.44 | -116.08 | -492.91 | 176.47 | Upgrade
|
Cash Interest Paid | 292.4 | 289.18 | 222.4 | 209.66 | 259.11 | 281.4 | Upgrade
|
Cash Income Tax Paid | - | 19.19 | -17.99 | 78.92 | -15.64 | 11.89 | Upgrade
|
Levered Free Cash Flow | -1,435 | -4,900 | -8,388 | 1,337 | -21,504 | -3,576 | Upgrade
|
Unlevered Free Cash Flow | -1,039 | -4,704 | -8,108 | 3,214 | -20,797 | -3,092 | Upgrade
|
Change in Net Working Capital | -3,361 | -576.35 | -8,098 | -10,079 | -3,398 | -4,647 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.